Data / Drug companies / Clindamycin phosphate
Clindamycin phosphate: 31 companies and 90 products in the FDA NDC directory
Clindamycin phosphate is listed in the FDA National Drug Code Directory by 31 companies, with 90 products in commercial distribution. 68 of the products (75.6%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution; gel; solution, and the newest product started marketing on March 23, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 31
- Products
- 90
- Generic (ANDA) products
- 68 (75.6%)
- Application numbers
- 37
- Routes
- Topical, Intravenous, Intramuscular, Vaginal
- Brand names
- Cleocin Phosphate, Clindamycin, Cleocin, Clindacin Etz, Clindacin, Xaciato, Clindacin P, Clindesse
- openFDA record search
- api.fda.gov
Companies that list clindamycin phosphate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Bryant Ranch Prepack | 9 | gel; solution | Generic drugs (ANDA) | March 31, 2021 |
| Baxter Healthcare Corporation | 8 | injection, solution | Generic drugs (ANDA) | June 28, 2017 |
| Medical Purchasing Solutions, LLC | 8 | injection, solution | Generic drugs (ANDA) | May 15, 2012 |
| Pharmacia & Upjohn Company LLC | 7 | injection, solution; cream | New drug applications (NDA) | February 3, 2024 |
| Padagis Israel Pharmaceuticals Ltd | 6 | solution; aerosol, foam | Generic drugs (ANDA) | March 31, 2021 |
| A-S Medication Solutions | 5 | solution; gel | Generic drugs (ANDA) | March 10, 2021 |
| Bryant Ranch Prepack | 4 | lotion; gel | Generic drugs (ANDA) | March 31, 2021 |
| E. Fougera & Co. a Division of Fougera Pharmaceuticals, LLC | 4 | solution; cream | Generic drugs (ANDA) | December 27, 2004 |
| Sun Pharmaceutical Industries, Inc. | 4 | lotion; solution | Generic drugs (ANDA) | October 1, 2022 |
| Bryant Ranch Prepack | 3 | solution; lotion | Generic drugs (ANDA) | March 31, 2021 |
| Medimetriks Pharmaceuticals, Inc. | 3 | swab; aerosol, foam | Generic drugs (ANDA) | June 15, 2013 |
| Mylan Pharmaceuticals Inc. | 3 | lotion; gel | Authorized generics (NDA) | August 11, 1992 |
| Baxter Healthcare Corporation | 2 | injection, solution | Generic drugs (ANDA) | June 28, 2017 |
| Glenmark Pharmaceuticals Inc., USA | 2 | aerosol, foam; gel | Generic drugs (ANDA) | January 23, 2024 |
| Henry Schein, Inc. | 2 | injection, solution | Generic drugs (ANDA) | January 9, 2022 |
| NorthStar Rx LLC | 2 | gel; lotion | Generic drugs (ANDA) | June 28, 2021 |
| Solaris Pharma Corporation | 2 | gel | Generic drugs (ANDA) | January 3, 2025 |
| Viona Pharmaceuticals Inc | 2 | gel; solution | Generic drugs (ANDA) | September 20, 2023 |
| Zydus Lifesciences Limited | 2 | solution; gel | Generic drugs (ANDA) | September 20, 2023 |
| Alembic Pharmaceuticals Inc. | 1 | gel | Generic drugs (ANDA) | April 4, 2024 |
| Alembic Pharmaceuticals Limited | 1 | gel | Generic drugs (ANDA) | April 4, 2024 |
| Amneal Pharmaceuticals NY LLC | 1 | gel | Generic drugs (ANDA) | August 8, 2022 |
| Aurobindo Pharma Limited | 1 | gel | Generic drugs (ANDA) | March 18, 2026 |
| Chartwell RX, LLC | 1 | solution | Generic drugs (ANDA) | February 8, 2018 |
| Encube Ethicals, Inc. | 1 | lotion | Generic drugs (ANDA) | January 19, 2022 |
| Oceanside Pharmaceuticals | 1 | gel | Authorized generics (NDA) | June 8, 2018 |
| Organon LLC | 1 | gel | New drug applications (NDA) | October 13, 2023 |
| Preferred Pharmaceuticals Inc. | 1 | solution | Generic drugs (ANDA) | August 6, 2021 |
| ProPharma Distribution | 1 | injection, solution | New drug applications (NDA) | October 2, 1972 |
| Rising Pharma Holdings, Inc. | 1 | solution | Generic drugs (ANDA) | March 23, 2026 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | May 15, 2012 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 26 | 28.9% |
| Gel | 21 | 23.3% |
| Solution | 19 | 21.1% |
| Lotion | 12 | 13.3% |
| Aerosol, foam | 6 | 6.7% |
| Cream | 4 | 4.4% |
| Swab | 1 | 1.1% |
| Suppository | 1 | 1.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 68 | 75.6% |
| New drug applications (NDA) | 18 | 20% |
| Authorized generics (NDA) | 4 | 4.4% |
Pharmacologic classes
| Class | Products |
|---|---|
| Lincosamide Antibacterial | 90 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.